Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). I. Response and toxicity in four different regimens.
D000208:Acute Disease; D000367:Age Factors; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D008722:Methods; D008875:Middle Aged; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D013866:Thioguanine; D007069:Ifosfamide; D003630:Daunorubicin